Claim Missing Document
Check
Articles

Found 22 Documents
Search

Self-Nanoemulsifying Drug Delivery System (SNEDDS): Challenges and Opportunities in Enhancing Drug Solubility Sabillah, Farhad Aulan; Fitriani, Hannie; Zubair, Muhammad Sulaiman; Syukri, Yandi
JSFK (Jurnal Sains Farmasi & Klinis) Vol 12 No 3 (2025): J Sains Farm Klin 12(3), December 2025
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.12.3.217-225.2025

Abstract

For oral medications, especially those in BCS Classes II and IV, poor aqueous solubility continues to be a significant formulation challenge. This problem restricts dosage consistency, therapeutic efficacy, and bioavailability. A promising method for improving the solubility and absorption of lipophilic drug compounds is the Self-Nanoemulsifying Drug Delivery System (SNEDDS). With ramifications for the pharmaceutical and medical domains, this narrative review attempts to investigate the synthesis, characterization, difficulties, and possible uses of SNEDDS in improving drug solubility. According to the standards of scientific merit, accessibility, and relevance, a total of 25 articles released within the previous five years were included. When SNEDDS meet gastrointestinal fluids, they spontaneously form nanoemulsions, which improves drug solubility. Oil, surfactant, and co-surfactant make up this system, which is optimized according to zeta potential (±30 mV), polydispersity index (<0.3), and particle size (<200 nm). Numerous studies have shown how well it works to enhance the pharmacokinetics and solubility of medications like thymoquinone, rosuvastatin, and curcumin. However, issues with excipient safety, formulation scalability, and long-term stability still exist. SNEDDS offers a versatile and efficient method for enhancing oral drug delivery, especially for nutraceuticals and health supplements. To fully realize its therapeutic and industrial potential, more research involving clinical validation, regulatory harmonization, and quality-by-design approaches is required.
Studi Bioinformatika Tanaman Genus Nigella terhadap Kanker Payudara Tipe Basal Berbasis Transkriptomik dan Farmakologi Jaringan Maulana, Saipul; Zubair, Muhammad Sulaiman; Azwar AR, Muhammad
Media Farmasi Vol 22 No 1 (2026): Media Farmasi Edisi April 2026
Publisher : Jurusan Farmasi Poltekkes kemenkes Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32382/mf.v22i1.2038

Abstract

Basal-type breast cancer (Triple-Negative Breast Cancer, TNBC) is an aggressive subtype characterized by poor prognosis and limited conventional therapeutic options due to the absence of hormone receptor and HER2 expression. To address this challenge, this study aims to elucidate the molecular mechanisms of compounds derived from the Nigella genus against basal-type breast cancer using a Network Pharmacology approach integrated with transcriptomic data. This in silico experimental study began with the identification of 433 bioactive compounds from the Nigella genus retrieved from databases, which were predicted to target a total of 2,227 potential proteins. Transcriptomic analysis was performed using the GSE7904 dataset, comparing 18 basal-type breast cancer samples with 7 normal control samples. Statistical analysis identified 9,666 significantly Differentially Expressed Genes (DEGs). Venn diagram intersection analysis between the compound targets and DEGs revealed 996 overlapping genes, which were designated as potential candidate targets. Protein–Protein Interaction (PPI) network topology analysis identified EGFR (Epidermal Growth Factor Receptor) as the top hub protein with a degree value of 110, followed by SRC (108) and PIK3CA (70). Functional enrichment analysis (KEGG) validated EGFR as a critical receptor in TNBC, initiating oncogenic signaling pathways such as MAPK and PI3K–Akt that drive basal-type cancer cell proliferation. Bioactive compounds from Nigella were predicted to exert their effects by interacting with membrane receptors and inhibiting tyrosine kinase activity. Therapeutic intervention targeting EGFR using bioactive compounds from the Nigella genus therefore represents a promising strategy to overcome resistance and aggressiveness in basal-type breast cancer.